Erin Harris

Cell & Gene: The Podcast

Science EN ↓ 151 episodes

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Be sure to visit the podcast's website and support the creator: www.buzzsprout.com

Author

Erin Harris

Category

Science

Podcast website

www.buzzsprout.com

Latest episode

Nov 19, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Inside the New Hybrid Roles for Cell Therapy Clinical Trials with Immatics' Michael Mehler 09.06.2022

We love to hear from our listeners. Send us a message. Autologous cell therapy clinical trials and products are very complex, and the stakeholder investment is diverse. Immatics' Director, Clinical Operations, Michael Mehler, explains why new hybrid roles operate in clinical operations, clinical supply chain, strategic operations, and medical affairs to help bridge the gap between the sponsor...

Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu 26.05.2022

We love to hear from our listeners. Send us a message. Dr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech's autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also explains Descartes-25, their allogeneic RNA cell therapy and the reasons for the move to "off-the-shelf," and why the future of...

Gene Therapy's Commercial Manufacturing Issues with Encoded Therapeutics' Andy Stober 12.05.2022

We love to hear from our listeners. Send us a message. Encoded Therapeutics' Chief Manufacturing Officer Andy Stober explains the unique commercial manufacturing issues in gene therapy and how to address them. Stober also shares some of the lessons he's learned, which may educate the next generation of gene therapy scientists to accelerate future manufacturing success. We also talk about...

Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D. 28.04.2022

We love to hear from our listeners. Send us a message. Amit Kumar, Ph. D., President and CEO at Anixa Biosciences details the company’s progress on its Phase 1 trial for ovarian cancer. We also discuss why the company’s ovarian cancer program is integral for initial proof of concept for other solid tumor indications. He covers why CAR-T therapy uses an existing hormone/hormone receptor relationshi...

Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris 14.04.2022

We love to hear from our listeners. Send us a message. Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me...

Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials 31.03.2022

We love to hear from our listeners. Send us a message. Rocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s AAV-focused CTGTAC meeting's takeaways will hold up throughout 2022, and more. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedI...

Inside Solid Tumor Therapies with BlueSphere Bio’s CEO Dr. David Apelian 17.03.2022

We love to hear from our listeners. Send us a message. BlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector needs to get right in the short term and why. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma 03.03.2022

We love to hear from our listeners. Send us a message. Cue Biopharma's Anish Suri, Ph. D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Conn...

REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies 17.02.2022

We love to hear from our listeners. Send us a message. REGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph. D., shares potential solutions to gene therapies' regulatory roadblocks and why the accelerated approval pathway is so pertinent.  Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors 03.02.2022

We love to hear from our listeners. Send us a message. Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gen...

Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech 20.01.2022

We love to hear from our listeners. Send us a message. Cellevolve Bio's founder and CEO. Dr. Derrell Porter shares his experience with starting up a cell therapy company and why we, as an industry, need to advocate for more Black leaders and leaders of color in the biotech industry. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on Li...

RNA's Advantages Over Other Cell Therapies with Cartesian's CSO 06.01.2022

We love to hear from our listeners. Send us a message. Dr. Michael Singer, CSO at Cartesian Therapeutics, details why RNA has advantages over other cell therapies, the company's three RNA trials, and the therapeutic benefit of multiple modifications. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Vor Biopharma's CEO on Genome Engineering of Hematopoietic Stem Cells 22.12.2021

We love to hear from our listeners. Send us a message. Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my...

AVROBIO on Patient Advocacy's Role in Clinical Trial Development & Recruitment 09.12.2021

We love to hear from our listeners. Send us a message. Fernanda Copeland, Global Head, Patient Advocacy & Engagement at AVROBIO, explains how to incorporate community education, patient feedback, and more to improve clinical trial development and recruitment. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton 24.11.2021

We love to hear from our listeners. Send us a message. Carisma Therapeutics’ Dr. Barton breaks down the latest in CAR-M technology as well as the company's Phase 1 First-in-Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me...

Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti 11.11.2021

We love to hear from our listeners. Send us a message. XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar 28.10.2021

We love to hear from our listeners. Send us a message. Dr. Amy Nicole Nayar, VP of US Patient Advocacy and Government Affairs at Novartis Gene Therapies explains what patient engagement should encompass in the cell and gene field as well as the unique challenges cell and gene therapy companies face where a patient engagement officer provides essential help. Subscribe to the podcast! Apple   |  Spo...

BridgeBio's Approach to Gene Therapy & Nearing the Clinic 14.10.2021

We love to hear from our listeners. Send us a message. BridgeBio's CEO of Gene Therapy, Dr. Eric David, explains the company's gene therapy programs for Canavan disease and congenital adrenal hyperplasia, their manufacturing plans, and the platform underpinning their novel approach to gene therapy. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene...

Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A 30.09.2021

We love to hear from our listeners. Send us a message. Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease. Subscribe to the podcast!...

Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO 16.09.2021

We love to hear from our listeners. Send us a message. Karen Kozarsky, Ph. D., Co-Founder and CSO of SwanBio, explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Chronic Lymphocytic Leukemia: A Patient's Perspective 02.09.2021

We love to hear from our listeners. Send us a message. Bob Levis was diagnosed with Chronic Lymphocytic Leukemia in 2002 and was one of the early experimental trial participants at Penn Medicine for Dr. Carl June’s CAR-T therapy. Bob shares his remarkable journey with CLL as well as his important work with the CLL Society. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: C...

State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO 19.08.2021

We love to hear from our listeners. Send us a message. Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector’s advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on Lin...

Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine 05.08.2021

We love to hear from our listeners. Send us a message. University of Pennsylvania’s Dr. Bruce Levine explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the "Cellicon Valley" name for its continued innovation in cell and gene therapy — and more. Subscribe to the podcast! Apple   |  Spotify |  YouTube Visit my w...

Hospitals And Advanced Therapies with Penn Medicine’s Kevin Mahoney 22.07.2021

We love to hear from our listeners. Send us a message. In this episode of Cell & Gene: The Podcast, University of Pennsylvania Health System’s CEO Kevin Mahoney talks to Host Erin Harris about how hospital systems must evolve to meet the needs of cell and gene therapy patients as these complex therapies are commercialized. They discuss what comprises UPHS and the ongoing innovation it brings t...

Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset 08.07.2021

We love to hear from our listeners. Send us a message. During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far t...

Listen to the Cell & Gene: The Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.